keyword
MENU ▼
Read by QxMD icon Read
search

pneumococcal vaccine adverse effect

keyword
https://www.readbyqxmd.com/read/29769176/using-feeding-to-reduce-pain-during-vaccination-of-formula-fed-infants-a-randomised-controlled-trial
#1
Netty G P Bos-Veneman, Marrit Otter, Sijmen A Reijneveld
OBJECTIVES: To assess the effectiveness and potential side effects of formula feeding to reduce pain during vaccination among infants. STUDY DESIGN: In the setting of well-baby clinics we recruited a community-based sample of full-term born infants who were already formula fed by the choice of the parents (n=48, aged 4-10 weeks) and received their first DTaP-IPV-HepB-Hib and pneumococcal vaccinations and randomised them into two groups. To evaluate pain experienced during vaccination we compared infants who drank formula feeding before, during and after vaccination with infants who did not...
May 16, 2018: Archives of Disease in Childhood
https://www.readbyqxmd.com/read/29752214/evaluation-of-pneumococcal-and-influenza-vaccination-coverage-in-rheumatology-patients-receiving-biological-therapy-in-a-regional-referral-hospital
#2
María Fernández-Prada, Anahy María Brandy-García, Omar Darío Rodríguez-Fonseca, Ismael Huerta-González, Federico Fernández-Noval, Carmen Martínez-Ortega
OBJECTIVE: Vaccination coverage for seasonal influenza and pneumococcus in rheumatology patients receiving biological treatment. To identify variables that predict vaccination adherence. MATERIAL AND METHOD: Descriptive cross-sectional study. The study involved rheumatology patients who initiated biological therapy between 01/01/2016 and 12/31/2016 in a regional referral hospital. Variables included sociodemographic information, diagnostic data, treating physician, referral to the vaccine unit and vaccination against pneumococcus with 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), as well as seasonal influenza (2016/17)...
May 8, 2018: Reumatología Clinica
https://www.readbyqxmd.com/read/29741289/grommets-ventilation-tubes-for-recurrent-acute-otitis-media-in-children
#3
REVIEW
Roderick P Venekamp, Paul Mick, Anne Gm Schilder, Desmond A Nunez
BACKGROUND: Acute otitis media (AOM) is one of the most common childhood illnesses. While many children experience sporadic AOM episodes, an important group suffer from recurrent AOM (rAOM), defined as three or more episodes in six months, or four or more in one year. In this subset of children AOM poses a true burden through frequent episodes of ear pain, general illness, sleepless nights and time lost from nursery or school. Grommets, also called ventilation or tympanostomy tubes, can be offered for rAOM...
May 9, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29288818/revaccination-after-autologous-hematopoietic-stem-cell-transplantation-is-safe-and-effective-in-patients-with-multiple-myeloma-receiving-lenalidomide-maintenance
#4
Meighan Palazzo, Gunjan L Shah, Olivia Copelan, Kenneth Seier, Sean M Devlin, Molly Maloy, Sheila Kenny, Hani Hassoun, Neha S Korde, Nikoletta Lendvai, Alexander M Lesokhin, Sham Mailankody, David J Chung, Guenther Koehne, C Ola Landgren, Heather Landau, Sergio A Giralt, Miguel-Angel Perales
Guidelines recommend vaccination starting 12 months after autologous hematopoietic stem cell transplant (aHCT), but there is varying practice for patients on maintenance therapy, with some centers not immunizing at all. Because of decreased vaccine rates among the general population causing loss of herd immunity, we aimed to establish the safety and efficacy of revaccinating multiple myeloma patients on lenalidomide maintenance (LM). Of the 122 patients who were vaccinated after aHCT between 2010 and 2014 at Memorial Sloan Kettering Cancer Center, 91 (75%) were on LM...
April 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29204064/vaccinations-in-immunosuppressive-dependent-pediatric-inflammatory-bowel-disease
#5
Huyen-Tran Nguyen, Phillip Minar, Kimberly Jackson, Patricia C Fulkerson
AIM: To determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population. METHODS: The electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29174323/pneumococcal-conjugate-vaccine-13-delivered-as-one-primary-and-one-booster-dose-1-1-compared-with-two-primary-doses-and-a-booster-2-1-in-uk-infants-a-multicentre-parallel-group-randomised-controlled-trial
#6
David Goldblatt, Jo Southern, Nick J Andrews, Polly Burbidge, Jo Partington, Lucy Roalfe, Marta Valente Pinto, Vasilli Thalasselis, Emma Plested, Hayley Richardson, Matthew D Snape, Elizabeth Miller
BACKGROUND: Infants in the UK were first offered a pneumococcal conjugate vaccine (PCV7) in 2006, given at 2 and 4 months of age and a booster dose at 13 months (2 + 1 schedule). A 13-valent vaccine (PCV13) replaced PCV7 in 2010. We aimed to compare the post-booster antibody response in UK infants given a reduced priming schedule of PCV13 (ie, a 1 + 1 schedule) versus the current 2 + 1 schedule and to assess the potential effect on population protection. METHODS: In this multicentre, parallel group, randomised controlled trial, we recuited infants due to receive their primary immunisations aged up to 13 weeks on first vaccinations by information booklets mailed out via the NHS Child Health Information Service and the UK National Health Application and Infrastructure Services...
February 2018: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/29049005/beliefs-attitudes-and-activities-of-healthcare-personnel-about-influenza-and-pneumococcal-vaccines
#7
Fatma Çiftci, Elif Şen, Nalan Demir, Orçun Çiftci, Serhat Erol, Oya Kayacan
OBJECTIVES: Vaccination of healthcare personnel (HCP) is an effective measure for preventing the spread of influenza among at-risk patients. This study was conducted to determine influenza vaccination rates and activities among HCP working at a tertiary healthcare setting. METHODS: This study included 470 HCP (85 physicians, 134 nurses, 53 healthcare assistants, 44 paramedics, 47 medical secretaries, and 107 auxillary staff members) working at the emergency, cardiology, chest diseases, and internal medicine departments with the largest volume of patients with vaccination indication of two large university hospitals with similar medical practices and work environment...
January 2, 2018: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28994899/prophylactic-antibiotics-for-preventing-pneumococcal-infection-in-children-with-sickle-cell-disease
#8
REVIEW
Angela E Rankine-Mullings, Shirley Owusu-Ofori
BACKGROUND: Persons with sickle cell disease (SCD) are particularly susceptible to infection. Infants and very young children are especially vulnerable. The 'Co-operative Study of Sickle Cell Disease' observed an incidence rate for pneumococcal septicaemia of 10 per 100 person years in children under the age of three years. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimens may be advisable for this population...
October 10, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28965937/pneumococcal-polysaccharide-vaccination-in-allogeneic-hematopoietic-stem-cell-transplantation-recipients-a-prospective-single-center-study
#9
Keiji Okinaka, Yukihiro Akeda, Saiko Kurosawa, Shigeo Fuji, Kinuko Tajima, Kazunori Oishi, Takahiro Fukuda
Few studies have evaluated the response of allogeneic hematopoietic stem cell transplantation [allo-HSCT] recipients to pneumococcal polysaccharide vaccine-23 [PPSV23] in the modern transplant era when more elderly patients undergo allo-HSCT. We administered a single dose of PPSV23 to 30 allo-HSCT recipients and evaluated serotype-specific antibody responses using IgG measured by enzyme-linked immunosorbent assay and opsonophagocytic assay [OPA] titers in a multiplexed opsonophagocytic killing assay. The median patient age was 54 years [range, 23-68], and the interval from allo-HSCT to vaccination was 756 days [range, 389-1903]...
September 29, 2017: Microbes and Infection
https://www.readbyqxmd.com/read/28838188/administering-multiple-injectable-vaccines-during-a-single-visit-summary-of-findings-from-the-accelerated-introduction-of-inactivated-polio-vaccine-globally
#10
REVIEW
Samantha B Dolan, Manish Patel, Lee M Hampton, Eleanor Burnett, Daniel C Ehlman, Julie Garon, Emily Cloessner, Elizabeth Chmielewski, Terri B Hyde, Carsten Mantel, Aaron S Wallace
Background: In 2013, the World Health Organization's (WHO's) Strategic Advisory Group of Experts (SAGE) recommended that all 126 countries using only oral polio vaccine (OPV) introduce at least 1 dose of inactivated polio vaccine (IPV) into their routine immunization schedules by the end of 2015. In many countries, the addition of IPV would necessitate delivery of multiple injectable vaccines (hereafter, "multiple injections") during a single visit, with infants receiving IPV alongside pentavalent vaccine (which covers diphtheria, tetanus, and whole-cell pertussis; hepatitis B; and Haemophilus influenzae type b) and pneumococcal vaccine...
July 1, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28811633/rapid-replacement-by-non-vaccine-pneumococcal-serotypes-may-mitigate-the-impact-of-the-pneumococcal-conjugate-vaccine-on-nasopharyngeal-bacterial-ecology
#11
Brenda Kwambana-Adams, Blake Hanson, Archibald Worwui, Schadrac Agbla, Ebenezer Foster-Nyarko, Fatima Ceesay, Chinelo Ebruke, Uzochukwu Egere, Yanjiao Zhou, Maze Ndukum, Erica Sodergren, Michael Barer, Richard Adegbola, George Weinstock, Martin Antonio
There is growing concern that interventions that alter microbial ecology can adversely affect health. We characterised the impact of the seven-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal carriage and the bacterial component of the nasopharyngeal microbiome during infancy. Newborns were recruited into three groups as follows: Group1 (n = 33) was the control group and comprised infants who received PCV7 after 6 months and came from unvaccinated communities. Group 2 (n = 30) came from unvaccinated communities and Group 3 (n = 39) came from vaccinated communities...
August 15, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28696530/immunogenicity-and-safety-of-single-dose-13-valent-pneumococcal-conjugate-vaccine-in-pediatric-and-adolescent-oncology-patients
#12
Te-Yu Hung, Rishi S Kotecha, Christopher C Blyth, Sarah K Steed, Ruth B Thornton, Anne L Ryan, Catherine H Cole, Peter C Richmond
BACKGROUND: Children receiving immunosuppressive treatment for cancer are at high risk for invasive pneumococcal disease. The 13-valent pneumococcal conjugate vaccine (PCV13) can prevent pneumococcal disease in healthy children; however, there is an absence of literature regarding the benefit of PCV13 in immunocompromised children with cancer. METHODS: A prospective, open-label cohort study recruited children between ages 1 and 18 years who were receiving active immunosuppressive therapy (AIT) or were within 12 months after completing immunosuppressive therapy (CIT)...
November 1, 2017: Cancer
https://www.readbyqxmd.com/read/28467293/a-randomized-open-label-study-to-investigate-the-effect-of-belimumab-on-pneumococcal-vaccination-in-patients-with-active-autoantibody-positive-systemic-lupus-erythematosus
#13
W Chatham, A Chadha, J Fettiplace, C Kleoudis, D Bass, D Roth, D Gordon
Objective Intravenous belimumab 10 mg/kg is approved as an add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus. This study aimed to assess the impact of belimumab on immune response to pneumococcal vaccination in patients with systemic lupus erythematosus. Methods This was a Phase 4, open-label study (GSK BEL115470; NCT01597492) conducted in the United States. Patients were randomized (7:9) to receive a 23-valent pneumococcal vaccination four weeks prior to (pre-belimumab cohort) or 24 weeks after (belimumab-concurrent cohort) commencing four-weekly belimumab 10 mg/kg intravenous treatment plus standard systemic lupus erythematosus therapy...
December 2017: Lupus
https://www.readbyqxmd.com/read/28429115/comparison-of-the-tolerability-of-newly-introduced-childhood-vaccines-in-the-netherlands
#14
COMPARATIVE STUDY
Jeanet M Kemmeren, Nicoline At van der Maas, Hester E de Melker
In 2011, the 7-valent conjugated pneumococcal vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) and universal hepatitis B vaccination has been introduced in the Netherlands. A questionnaire study was conducted to assess the tolerability of DTaP-IPV-Hib + PCV7 (PCV7-cohort), DTaP-IPV-Hib + PCV10 (PCV10-cohort), and DTaP-IPV-Hib-HepB + PCV10 (HepB-cohort). Parents were asked to report in questionnaires local reactions and systemic adverse events (AEs) before and after vaccination of their infant at 2, 3, 4, and 11 months of age...
June 2017: European Journal of Pediatrics
https://www.readbyqxmd.com/read/28352933/erythema-multiforme-following-pneumococcal-vaccination
#15
Alexandra Monastirli, Efstathia Pasmatzi, George Badavanis, Dionysios Tsambaos
Erythema multiforme (EM) is an acute and usually self-limited immune-mediated mucocutaneous disorder that is a hypersensitivity reaction to drugs, infections, and vaccines. Clinically, it is characterized by maculopapular, target-like lesions symmetrically distributed on the extremities (minor form) or additionally affecting one or more mucous membranes and causing epidermal detachment involving < 10% of the total body surface area (major form). We report a novel association between pneumococcal vaccination and the development of EM in a 2...
March 2017: Acta Dermatovenerologica Alpina, Panonica, et Adriatica
https://www.readbyqxmd.com/read/28242152/-post-licensure-safety-surveillance-for-prevenar-13-%C3%A2-in-france
#16
M-S Agier, S Marchand, N Paret, S Gautier, A-P Jonville-Béra
OBJECTIVE: To describe the profile and the incidence of adverse events (AEs) reported with Prevenar 13® since its commercialization. METHOD: Analysis of all adverse events reported with Prevenar 13® in France between 1st July 2010 and 31 October 2014. RESULTS: In 4 years and 4 months, 376 AEs, including 252 severe (67%), were recorded, 83 of which occurred following an injection of Prevenar 13® alone: 39 cutaneous AEs, 16 neurological AEs, four cases of collapse or shock, nine cases of fever, and one of thrombocytopenia...
May 2017: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/28145151/factors-associated-with-influenza-and-pneumococcal-vaccine-uptake-among-rheumatoid-arthritis-patients-in-denmark-invited-to-participate-in-a-pneumococcal-vaccine-trial-immunovax_ra
#17
Mtt Nguyen, H Lindegaard, O Hendricks, N Friis-Møller
OBJECTIVE: This study investigates predictors of influenza and pneumococcal vaccine coverage among rheumatoid arthritis (RA) patients, and explores possible differences according to type of RA therapy. METHOD: RA patients from two clinics in the region of Southern Denmark were informed about the survey during scheduled follow-up visits. The questionnaire included questions concerning previous influenza and pneumococcal vaccine uptake, attitudes about vaccination, and socio-demographic factors...
November 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28133957/efficacy-and-safety-of-vaccination-in-pediatric-patients-with-systemic-inflammatory-rheumatic-diseases-a-systematic-review-of-the-literature
#18
Sandra Sousa, Ana Catarina Duarte, Inês Cordeiro, Joana Ferreira, Maria João Gonçalves, Tiago Meirinhos, Teresa Martins Rocha, Vasco C Romão, Maria José Santos
INTRODUCTION: Children and adolescents with systemic rheumatic diseases have an increased risk of infections. Although some infections are vaccine-preventable, immunization among patients with juvenile rheumatic diseases is suboptimal, partly due to some doubts that still persist regarding its efficacy and safety in this patient population. OBJECTIVES: To review the available evidence regarding the immunological response and the safety of vaccination in children and adolescents with systemic inflammatory rheumatic diseases (SIRD)...
January 2017: Acta Reumatológica Portuguesa
https://www.readbyqxmd.com/read/28120848/nanogel-based-nasal-ghrelin-vaccine-prevents-obesity
#19
T Azegami, Y Yuki, S Sawada, M Mejima, K Ishige, K Akiyoshi, H Itoh, H Kiyono
Obesity is associated with multiple comorbidities such as cardiovascular diseases and has a huge economic impact on the health-care system. However, the treatment of obesity remains insufficient in terms of efficacy, tolerability, and safety. Here we created a nasal vaccine against obesity for the first time. To avoid the injectable administration-caused pain and skin-related adverse event, we focused on the intranasal route of antigen delivery. We developed a vaccine antigen (ghrelin-PspA (pneumococcal surface protein A)), which is a recombinant fusion protein incorporating ghrelin, a hormone that stimulates food intake and decreases energy expenditure, and PspA, a candidate of pneumococcal vaccine as a carrier protein...
September 2017: Mucosal Immunology
https://www.readbyqxmd.com/read/28116747/pneumococcal-vaccines-for-preventing-pneumonia-in-chronic-obstructive-pulmonary-disease
#20
REVIEW
Julia Ae Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood-Baker
BACKGROUND: People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs. OBJECTIVES: To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD. SEARCH METHODS: We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms...
January 24, 2017: Cochrane Database of Systematic Reviews
keyword
keyword
96756
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"